Soleno Therapeutics Inc (SLNO) - Total Liabilities
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has total liabilities worth $112.59 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Soleno Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Soleno Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SLNO total asset value.
Soleno Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Soleno Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanxi Securities Co Ltd
SHE:002500
|
China | CN¥71.93 Billion |
|
Henan Yuneng Holdings Co Ltd
SHE:001896
|
China | CN¥27.92 Billion |
|
YiDong Electronics Technology Co. Ltd.
SHE:301123
|
China | CN¥1.21 Billion |
|
Grindr Inc
NYSE:GRND
|
USA | $474.58 Million |
|
People.Cn Co Ltd
SHG:603000
|
China | CN¥1.37 Billion |
|
Aerospace CH UAV Co Ltd
SHE:002389
|
China | CN¥2.14 Billion |
|
Steadfast Group Limited
F:1S6
|
Germany | €3.80 Billion |
|
Qi An Xin Technology Group Inc
SHG:688561
|
China | CN¥6.56 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Soleno Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Soleno Therapeutics Inc (SLNO) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Soleno Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Soleno Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $113.72 Million | +32.44% |
| 2024-12-31 | $85.86 Million | +270.34% |
| 2023-12-31 | $23.18 Million | +43.56% |
| 2022-12-31 | $16.15 Million | -9.07% |
| 2021-12-31 | $17.76 Million | -8.62% |
| 2020-12-31 | $19.43 Million | -16.32% |
| 2019-12-31 | $23.23 Million | +82.33% |
| 2018-12-31 | $12.74 Million | +2.01% |
| 2017-12-31 | $12.49 Million | +486.33% |
| 2016-12-31 | $2.13 Million | -57.21% |
| 2015-12-31 | $4.98 Million | -73.42% |
| 2014-12-31 | $18.73 Million | -52.53% |
| 2013-12-31 | $39.45 Million | +7.47% |
| 2012-12-31 | $36.71 Million | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more